12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Deals

Amarantus BioScience Inc., Power3 deal

On Dec. 26, 2012, Amarantus said it purchased all of Power3's IP and assets for the diagnosis of multiple neurodegenerative diseases and cancers for $40,000. As part of the transaction with Power3, which...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >